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There has been significant interest in understanding how interactions between the host
immune system and the gut microbiota regulate intestinal homeostasis. Recent data
suggest that the Nod-like receptor (NLR) family of PRRs regulate both the composition
of the gut microbiota and innate immune signaling pathways that prevent pathologic
intestinal inflammation and tumorigenesis. In this review, we will focus on NLRP6 and
NLRP12, two members of the NLR family that have emerged as important players in the
maintenance of intestinal homeostasis, and discuss the signaling pathways engaged by
these receptors as well as the current models of how these receptors protect against the
development of colitis and tumorigenesis.
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Introduction
Since the discovery that host bacterial recognition pathways are
critical for maintaining intestinal homeostasis [1], there have been
numerous studies demonstrating how members of the Nod-like
receptor (NLR) family play an important role in both promoting
host defense against invasive pathogens and reducing host suscep-
tibility to chemically-induced colitis and subsequent tumorigenesis
[2–9]. NLRs have been traditionally considered as PRRs, in that
they are activated in response to conserved structural motifs found
in microbes or PAMPs, such as peptidoglycan or flagellin [10,11].
More recently, NLRs, particularly NLRP3, have been implicated
in recognizing endogenous stimuli related to cellular injury, or
damage-associated molecular patterns, which can result in sterile
inflammation [12]. NLRs are characterized by a tripartite struc-
ture consisting of (i) a variable N-terminal protein–protein inter-
action domain, (ii) a central nucleotide-binding oligomerization
(NOD) domain that mediates the self-oligomerization occurring
during activation [13], and (iii) a C-terminal leucine-rich repeat
(LRR) involved in ligand specificity. The N-terminal domain of
an NLR can be defined as a caspase recruitment domain (CARD),
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pyrin domain (PYD), acidic, transactivating domain or baculovirus
inhibitor repeat. There are at least 23 identified human NLRs, and
34 NLRs have been identified in mice. A standardized nomencla-
ture system [14] categorizes the NLR family into four subfamilies
based on the type of N-terminal domain. Two NLRs in particular
(NLRP6 and NLRP12), both highly expressed in the intestine, act
as negative regulators of intestinal inflammation and tumorigen-
esis [7–9,15,16]. NLRP6 and NLRP12 belong to the subfamily of
NLRs that contain an N-terminal (PYD), which can interact with
other PYD-containing proteins that are important for downstream
signaling events. Multiple members of the NLR family, including
NOD1, NOD2, NLRC4, and NLRP3, have been implicated in main-
taining intestinal homeostasis [2, 4, 15, 17, 18]. These members
are relatively well-characterized and the nature of their upstream
ligands have been identified. In this review, we will focus on the
recently recognized roles of NLRP6 and NLRP12, two NLRs whose
upstream agonist has not yet been identified, in the protection
against intestinal inflammation and tumorigenesis.
NLRP6 and NLRP12 participate in multiple
signaling pathways
Early in vitro studies have implicated both NLRP6 and NLRP2
in inflammasome formation [19, 20]. Inflammasomes are
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multiprotein complexes whose assembly is mediated by the
adaptor protein apoptosis-associated speck-like protein (ASC).
ASC possesses both a carboxy terminal, CARD, and a PYD, and,
therefore, is capable of interacting with NLRs that also contain
a PYD domain through homophilic protein–protein interactions.
The current model of inflammasome assembly hypothesizes
that NLR activation by its agonist results in oligomerization
through the NOD domain of the receptor. Subsequently, through
CARD–CARD and PYD–PYD protein–protein interactions, a
large macromolecular complex is assembled, which serves as a
platform for procaspase-1 recruitment. After recruitment to the
inflammasome complex, procaspase-1 self-cleaves into active
caspase-1 [21]. Caspase-1 then cleaves pro-IL-1β and pro-IL-18
into their mature and active forms [22].
Both NLRP6 andNLRP12 have been demonstrated to colocalize
with ASC in a characteristic speckled pattern within the cytoplasm.
Colocalization is dependent on the presence of the PYD in both
NLRP6 and NLRP12 [19,20]. Thus, both NLRP6 and NLRP12 have
been considered as members of the inflammasome. However, in
these studies, which employed overexpression of NLR proteins,
a direct physical interaction between ASC and either NLRP6 or
NLRP12 could not be demonstrated. This may reflect the poor sol-
ubility of ASC upon oligomerization after activation [23]. Alter-
natively, the interaction between ASC and NLRP6 or NLRP12 may
be highly transient in nature. Nonetheless, coexpression of ASC
and NLRP6 in COS-7L cells in vitro resulted in increased IL-1β
production that was dependent on the availability of caspase-1
and the NLRP6 PYD [20]. Similarly, NLRP12 has been demon-
strated to cooperate with ASC to promote caspase-1 activation
and production of IL-1β in a PYD-dependent manner [19]. Consis-
tent with a role for NLRP12 in the production of IL-1β and IL-18,
NLRP12-deficient mice have increased mortality to infection by
an attenuated strain of Yersinia pestis in comparison to WT mice
[24]. In this model, IL-1β production by bone marrow-derived
macrophages (BMDMs) and serum IL-18 levels are decreased in
NLRP12-deficient mice. However, IL-1β and IL-18 production are
not completely abolished, suggesting redundancy in cytokine pro-
duction pathways. Reduced IL-18 production was also observed
in NLRP6-deficient mice, which was associated with increased
susceptibility to chemically-induced colitis and colitis-associated
tumorigenesis (discussed further below) [7–9]. Evidence for the
involvement of NLRP6 and NLRP12 in inflammasome formation
and activation remains largely derived from in vitro studies in
which these proteins are overexpressed. To date, the ligand that
stimulates NLRP6 or NLRP12 activity remains unknown. Thus,
direct evidence that NLRP6 or NLRP12 activate the inflammasome
under physiologic conditions in vivo has been difficult to obtain.
In addition to a potential role in inflammasome signaling, in
vitro studies have also suggested that NLRP6 and NLRP12 are
positioned upstream of NF-κB and MAPK in cell signaling path-
ways (Fig. 1). Although NLRP6 and NLRP12 are both unable to
activate NF-κB alone in luciferase reporter assays, there is syner-
gistic activation of NF-κB together with ASC when either NLRP6 or
NLRP12 were co-transfected with ASC in 293T cells [19,20]. More
recently, NLRP6 was shown to be a negative regulator of canon-
ical NF-κB signaling. Specifically, stimulation of NLRP6-deficient
BMDMs with bacterial TLR-2 and TLR-4 ligands, results in sig-
nificantly upregulated NF-κB and MAPK (ERK) signaling, culmi-
nating in increased cytokine production such as TNF-α and IL-6
[25]. Consequently, NLRP6-deficientmice are resistant to systemic
bacterial infection, resulting from greater induction of proinflam-
matory cytokines, increased bacterial clearance, and survival [25].
However, whether NLRP6 also participates in host defense against
gastrointestinal infections remains to be investigated.
NLRP12 has also been shown to downregulate NF-κB responses
to TLR agonists, and its expression is reduced in response to TLR
stimulation in vitro in THP-1 cells [16,26]. However, it is unclear
whether NRLP12 acts primarily on the noncanonical versus canon-
ical pathway. Early in vitro studies implementing siRNA knock-
down of NLRP12 expression or protein overexpression suggested
that NLRP12 negatively regulates the noncanonical NF-κB path-
way. More specifically, NLRP12 directly associates with the NF-κB-
inducing kinase (NIK) through its NOD and LRR domains, leading
to proteasome-mediated degradation of NIK [27]. NIK induces
NF-κB activation by inducing the phosphorylation of the non-
canonical NF-κB effector p100, which is then processed into the
p52 subunit that transcriptionally activates p52-regulated genes.
Other in vitro protein overexpression studies show that NLRP12
also downregulates TLR-mediated pathways through association
with IRAK-1 [26]. Furthermore, knockdown of NLRP12 expres-
sion by siRNAs in THP-1 cells results in higher expression of IL-6
in response to TLR ligands as well as to Mycobacterium tubercu-
losis [26]. However, these in vitro results were not reproduced
in in vivo models of pulmonary infection with M. tuberculosis or
Klebsiella pneumonia [28]. Specifically, although TNF-α and IL-6
production in bone marrow-derived DCs (BMDCs) were signifi-
cantly elevated in NLRP12-deficient cells compared with that in
WT cells, NLRP12-deficient mice did not exhibit any differences
in disease outcome compared with WT mice [28], suggesting
that other NLRs may be able to substitute for NLRP12. In the
gastrointestinal tract, NLRP12 negatively regulates inflammatory
responses during chemically induced colitis [15, 16] (discussed
further below). Although these studies point to a role for NLRP12
in regulating NF-κB, at least one study has demonstrated no sig-
nificant difference in NF-κB activation in response to Yersinia or
TNF-α [24]. It is therefore possible that the nature of the stim-
ulus and the specific context in which it is given is important in
revealing a significant function for NLRP12 in NF-κB regulation.
NLRP6 maintains intestinal homeostasis by
regulating the gut microbiome
A significant role for the gut microbiota in dictating host suscep-
tibility to intestinal disease has emerged. This is highlighted by
studies showing transmissibility of intestinal disease by co-housing
of laboratory mice [7, 17, 29, 30]. Dextran sulfate sodium (DSS)
can be used to induce a disease model of colitis, characterized
by mucosal ulceration and disruption of the epithelial barrier
that results in commensal-driven inflammation arising from
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Figure 1. Multiplemechanisms involved in suppressing inflammation and tumorigenesis by NLRP6 andNLRP12. NLRP6 regulates IL-18 production,
which helps to maintain a healthy microbiome and promotes epithelial repair (1). IL-18 also downregulates IL-22BP (2), thereby allowing IL-22 to
participate in epithelial proliferation and repair of epithelial damage. NLRP6-deficiency is also associated with persistent IL-22BP production by
primarily MCHII+CD11c+ cells [35], which results in inhibition of the reparative activity of IL-22 (2). IL-18 potentially upregulates IFN-γ production,
which promotes antitumor responses (3). In the absence of Nlrp6, the microbiome is altered, leading to the accumulation of potentially colitogenic
bacteria, or dysbiosis (4), which can upregulate inflammatory factors, including CCL5 to promote inflammation and tumorigenesis especially in the
presence of a damaged epithelial barrier (5). The persistence of epithelial damage allows bacterial translocation into the colonicmucosa to stimulate
an aberrant inflammatory response by immune cells that promote inflammation and tumorigenesis (5). Similarly, NLRP12 negatively regulates
NF-κB responses (6) although there are discordant observations regarding canonical versus noncanonical NF-kB pathways. NLRP12 deficiency is
also associated with increased inflammation followed by tumorigenesis related to uncontrolled NF-κB signaling in either hematopoietic and/or
nonhematopoietic cells (6).
bacterial translocation into the mucosa. Mice deficient in several
of the NLRs have increased susceptibility to DSS-induced colitis
associated with microbiome changes distinct from that in WTmice
[7, 17, 31], including NLRP6. NLRP6-deficient mice developed
more severe DSS-induced colitis compared with WT mice; how-
ever, after co-housing WT and NLRP6-deficient mice together for
4 weeks, WT mice acquire the same phenotype as NLRP6-deficient
mice [7]. Microbiome profiles obtained by 16S rRNA sequencing
revealed distinct microbial communities in WT and NLRP6-
deficient mice [7]. In fact, NLRP6-deficient and ASC-deficient
mice exhibit similar bacterial community profiles, suggesting an
inflammasome-dependent regulation of the composition of the gut
microbiota. Interestingly, mice deficient in other inflammasome-
related NLRs, such as NLRC4, NLRP10, NLRP12, and AIM2, did
not affect the susceptibility of WT mice to colitis after co-housing
[7]. Notably, bacterial phylotypes that are significantly different
between WT and NLRP6-deficient mice include Prevotella, and a
member of the family Prevotellaceae as well as the phylum TM7
[7]. Antibiotic treatment ofNlrp6−/− mice results in the disappear-
ance of both Prevotellaceae and TM7 and is associated with the
amelioration of DSS-induced colitis [7]. IL-18-deficient mice, but
not IL-1R-deficient mice, are also able to transmit increased sus-
ceptibility to colitis to WTmice. Moreover, the Nlrp6−/− mice used
in this study have decreased levels of IL-18 in the serum and colon
at baseline, suggesting that the altered microbiome in NLRP6-
deficient mice is related to defective IL-18 production [7]. Changes
in the microbiome not only affect susceptibility to colitis, but also
to inflammation-associated tumorigenesis under the AOM/DSS
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model, in which mice are given an intraperitoneal injection of the
carcinogen azoxymethane (AOM) followed by multiple rounds of
DSS treatment [7, 30]. This phenotype is shared by both NLRP6-
deficient and ASC-deficient mice and is transmissible to WT mice.
The Nlrp6−/− mice used in both colitis and tumor development
studies have elevated levels of CCL5 at baseline, associated with
abnormal crypt hyperplasia and increased immune cell infiltra-
tion. When CCL5-deficient mice are cohoused with Nlrp6−/− mice,
CCL5-deficient mice do not develop increased colitis or tumors,
suggesting that the dysbiotic microbiota promotes both inflamma-
tion and tumorigenesis that is mediated by CCL5 (Fig. 1) [7,30].
The above results are exciting in that they suggest that cer-
tain bacteria within the microbiota are potentially colitogenic or
tumorigenic and the accumulation of these bacteria is regulated
by NLRP6 and the inflammasome. This indicates possible ther-
apeutic targets for the treatment or prevention of inflammatory
bowel disease and colitis-associated colorectal cancer. However,
the results of these studies should also be interpreted with some
caution. First, the community structure of the gut microbiome in
IL-18-deficient mice remains distinct from that of NLRP6-deficient
mice, and therefore it is likely that additional factors contribute
to the microbiome of NLRP6-deficient mice. In addition, Asc−/−
mice cross-fostered with WT mothers do not develop more severe
colitis compared with noncross-fostered Asc−/− mice, suggesting
that ASC deficiency alone is insufficient for the development of a
dysbiotic microbiome capable of increasing disease severity, and
that environmental rather than genetic factors contribute tomicro-
biome composition. Finally, alterations in colon crypt morphology
and impaired serum levels of IL-18 were not observed in colonies
of NLRP6-deficient mice at other institutions [8], suggesting that
there may be colony-dependent effects. As previous studies eval-
uating TLR-deficient mice determined that the composition of the
microbiome is largely dependent on maternal transmission of the
microbiota from isolated mouse colonies rather than on any TLR
defect [32], it remains possible that the observed microbiome
changes in NLRP6-deficient mice [7] are related more to differ-
ences in ancestry rather than to an immune defect. Additional
experiments with germfree WT and Nlpr6−/− mice may provide
additional insight into the relationship between NLRP6 and the
gut microbiome.
NLRP6 has also been implicated in the regulation of the gut
microbiome to affect stress-induced small intestinal disease in the
water-avoidance stress (WAS) model of irritable bowel syndrome
[32], in which mice are regularly placed on a platform surrounded
by water for 10 days. Inflammation, interestingly, is limited to the
small intestine and is associated with a reduction in NLRP6 expres-
sion in the epithelium and decreased IL-1β and IL-18 production
[33]. This phenotype is also transmissible to co-housed WT mice
not subjected to WAS, and 16S rRNA sequencing revealed dis-
tinct microbiome changes in the luminal contents of the small
intestine with changes in relative abundance in multiple bacterial
families. Pretreatment of mice with a Lactobacillus-containing pro-
biotic significantly reduced the severity of WAS-induced intestinal
inflammation and also ‘‘normalized’’ the microbiome. It remains
to be determined whether the observed microbiome changes are
mediated by NLRP6 signaling and directly cause intestinal inflam-
mation, rather than are a consequence of it.
NLRP6 maintains intestinal homeostasis by
regulating epithelial repair and proliferation
As discussed above, impaired IL-18 production may be associ-
ated with the development of an altered microbiota, or dysbio-
sis, that predisposes to colitis and tumorigenesis. However, IL-18
also promotes epithelial repair by (i) MyD88 signaling [1, 34];
and (ii) downregulating the expression of IL-22 binding protein
(IL-22BP) [35] (Fig. 1). IL-22BP interacts with IL-22, a cytokine
which promotes epithelial proliferation during wound healing, to
prevent it from binding to its cognate receptor [36, 37]. Indeed,
IL-18-deficient mice have more severe DSS-induced colitis, which
is associatedwith impaired epithelial repair [4]. Consistently, mice
deficient in caspase-1 and ASC also have decreased IL-18 produc-
tion and greater severity of colitis compared with WT mice, a
condition which can be rescued by the administration of recombi-
nant IL-18 to caspase-1−/− mice [4]. Caspase-1 and IL-18-deficent
mice also develop more inflammation-associated tumors, with the
former exhibiting decreased IFN-γ and STAT1 signaling, both of
which are important for antitumor responses [5]. NLRP6-deficient
mice also have decreased IL-18 levels in the serum and in the
colon tissue during the acute inflammatory response to DSS in the
AOM/DSS model, which may explain defects in epithelial restitu-
tion observed in these mice [8]. Consistent with this hypothesis,
NLRP6-deficient mice also fail to downregulate IL-22BP after DSS-
induced injury in the AOM/DSS tumor model [35]. Interestingly,
although studies suggest that NLRP6 is expressed primarily in the
epithelium [7], bone marrow chimeric experiments suggest that
Nlrp6 functions in the hematopoietic cell compartment rather than
in nonhematopoietic cells [8]. Consistent with this observation,
NLRP6 has been implicated in negatively regulating inflammatory
responses in immune cells (discussed further below). In addition,
Nlrp6 mRNA expression is inducible such as by PPAR-γ agonists
[33,38], andwhether this occurs in hematopoietic cells in response
to an as yet unidentified ligand to suppress tumorigenesis remains
to be determined.
As a consequence of poor intestinal repair of DSS-induced
epithelial damage, the epithelium barrier remains compromised
in NLRP6-deficient mice, resulting in significantly elevated levels
of proinflammatory, protumorigenic cytokines, and chemokines,
likely in response to translocated bacteria [8]. Gene expression
profiling of tumor and normal tissue in NLRP6-deficient and WT
mice also demonstrated that NLRP6 is important for the negative
regulation of factors involved in epithelial proliferation such as
Wnt and Notch target genes [9]. Thus, although NRLP6-deficient
mice exhibit increased inflammatory responses, consistent with a
negative regulatory role in NF-κB and MAPK signaling as demon-
strated in in vivo infectionmodels [25], its role within the intestine
is likely more related to the regulation of IL-18 production.
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NLRP12 maintains intestinal homeostasis
by negatively regulating inflammatory
responses
Similar to NLRP6, NLRP12 also plays an important role in
protecting against the development of DSS-induced colitis and
inflammation-associated tumorigenesis with AOM/DSS [15, 16]
(Fig. 1). In contrast to NLRP6, NLRP12-deficient mice are unable
to transmit colitis susceptibility to WT mice after co-housing, sug-
gesting that a mechanism distinct from microbiome regulation
is responsible for its protective function [7]. Indeed, consistent
with a role as a negative regulator of NF-κB and MAPK responses,
NLRP12-deficient mice develop more severe colitis than WT mice.
However, the precise mechanism by which NLRP12 negatively
regulates NF-κB to protect against colitis and colitis-associated
tumorigenesis remains to be determined as the two groups that
reported this phenotype suggest disparate mechanisms [15, 16].
In both studies, the colitis in Nlrp12−/− mice is associated with
significantly increased extent of disease, the production of proin-
flammatory cytokines and/or chemokines and the activation of
NF-κB and ERK signaling in the colon [15, 16]. However, bone
marrow chimeric experiments performed in the study by Zaki
et al. [16] suggest that NLRP12 functions in the hematopoietic cell
compartment to suppress tumorigenesis (Fig. 1). Moreover, the
increased inflammatory responses are related to increased canon-
ical and not noncanonical NF-κB activation. This is consistent with
the observation that NLRP12-deficient BMDMs exhibit increased
canonical, but not noncanonical, NF-κB and ERK activation in
response to TLR ligands since excessive inflammatory responses
to commensal bacteria in the setting of a breached epithelial bar-
rier from DSS-induced colitis contributes to increased colitis and
tumorigenesis. However, bone marrow chimeric experiments by
Allen et al. [15] suggest that although NLRP12 function in both the
hematopoietic and nonhematopoietic compartments is important
for early disease manifestations of DSS-induced colitis, the non-
hematopoietic compartment is ultimately important for limiting
tumor numbers [15]. Furthermore, disease severity in NLRP12-
deficient mice is predominantly associated with dysregulation of
the noncanonical rather than canonical NF-κB pathway, consis-
tent with previous studies by the same group demonstrating that
NLRP12 interacts with NIK to regulate the p52 subunit of NF-κB
[26]. The differences between studies can be partially reconciled
by the fact that the study by Allen et al. also observed increased
canonical NF-κB signaling in BMDCs after TLR ligand exposure in
NLRP12-defiicent mice; moreover, noncanonical NF-κB signaling
can influence both the canonical pathway and MAPK signaling
[39–41]. The discrepancy in findings regarding whether NLRP12
is important in the hematopoietic or nonhematopoietic compart-
ments is more difficult to explain. The analysis of NF-κB activation
was in different cell types (BMDMs versus BMDCs), and there may
have been differences in the colonies of Nlrp12−/− mice (e.g. the
microbiota) that may have influenced the outcome of the bone
marrow chimeric experiments. Regardless, taken together, these
studies suggest an important role for NLRP12 in limiting inflam-
matory responses within the colon.
Conclusions
Exciting progress has been made in understanding how host
immune receptors promote intestinal health. However, as demon-
strated above, more than one mechanism may be important. Both
NLRP6 and NLRP12 play protective roles in limiting the devel-
opment of chemically-induced injury and carcinogenesis through
regulation of IL-18 production, NF-κB and MAPK-dependent
inflammatory responses, and prevention of dysbiosis. However,
additional confirmatory experiments are needed to clarify the rel-
ative contributions of these different mechanisms in the regulation
of intestinal homeostasis and to determine whether other mecha-
nisms are involved. Discrepancies in the identity of the cell type(s)
important for NLRP6 or NLRP12 function within the intestine and
the differential impact of NLRP12 on canonical versus canonical
NF-κB signaling remain. Moreover, our understanding of NRLP6
and NLRP12 function in intestinal homeostasis has been based
entirely on one model of colitis involving DSS-induced epithelial
injury. As additional mechanisms can be involved in the devel-
opment of inflammatory bowel disease in humans, it would be
important to also determine the effect of NLRP6 or NLRP12 defi-
ciency in other models of colitis. A role for NLRP6 or NLRP12 in
host defense against infections involving the intestine also remains
to be investigated. Further advances in understanding the mecha-
nism by which these two NLRs protect the intestine will be aided
by the identification of the ligand or stimulus recognized by each
NLR. This will also facilitate the development of therapeutics that
modulate NLRP6 and NLRP12 function within the intestine to pre-
vent or treat inflammation and cancer.
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